Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
ADMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.88 - $23.64
Previous CloseN/A
Volume407.39K
Average Volume (3M)2.48M
Market Cap
$4.02B
Enterprise Value$4.92B
Total Cash (Recent Filing)$22.75M
Total Debt (Recent Filing)$44.22M
Price to Earnings (P/E)20.9
Beta1.19
Next Earnings
May 07, 2025EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding236,390,260
10 Day Avg. Volume3,234,635
30 Day Avg. Volume2,480,154
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.51
Price to Cash Flow (P/CF)40.20
P/FCF Ratio42.00
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit55.30
Enterprise Value/Ebitda49.94
Forecast
1Y Price Target
$28.50Price Target Upside71.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Production OutputIg yield enhancement approval could lead to a 20% increase in production output, boosting sales and margins.
Supply Chain StabilityRecently signed long-term duration source plasma contracts remove supply chain uncertainties.
Bears Say
Financial ReportingADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.
---
Ownership Overview
3.52% Insiders
20.83% Mutual Funds
12.85% Other Institutional Investors
33.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $5.88 and its highest was $23.64 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $4.02B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is May 07, 2025 which is in 57 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Mar 03, 2025. The company reported $0.141 earnings per share for the quarter, missing the consensus estimate of $0.15 by -$0.009.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.15.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 236,390,260 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.141 in its last earnings report, missing expectations of $0.15. Following the earnings report the stock price went up 7.454%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
---
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.50 (71.58% Upside)
$28.50 (71.58% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
176.29%
12-Months-Change
Fundamentals
Return on Equity
81.65%
Trailing 12-Months
Asset Growth
48.45%
Trailing 12-Months
Company Description
ADMA Biologics
ADMA Biologics (ADMA) is a biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The company's core products are derived from human blood plasma and include intravenous immune globulin (IVIG) and other plasma-based medications designed to support the immune systems of individuals with compromised immune function. ADMA operates within the biotechnology and pharmaceuticals sectors, with a focus on delivering innovative therapies that address unmet medical needs.
---
ADMA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook for ADMA Biologics, with significant revenue growth and strategic advancements in high-titer plasma supply and ASCENIV's market potential. However, there is some uncertainty with pending FDA approval and delayed audit completion.Read More>---
ADMA Stock 12 Month Forecast
Average Price Target
$28.50
▲(71.58% Upside)
Technical Analysis
Best Analysts Covering ADMA
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+72.70%
reiterated a buy rating 6 days ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +72.70% per trade.
---